• Mashup Score: 0

    What’s next for the cell and gene therapy market? In Deloitte’s state of the industry survey, stakeholders from across the ecosystem share insights on their optimism for the year ahead and identify areas for caution.

    Tweet Tweets with this article
    • Over 60% of clinical stage #CellTherapy and #GeneTherapy innovators seek partnerships and over 50% are raising capital for commercialization. Explore the future of #PersonalizedMedicine in our report. https://t.co/ubz8iHh7Pm

  • Mashup Score: 2

    Analyses of large population-based cohorts and clinical trials show that using polygenic scores to account for variability in PSA levels improves detection of prostate cancer, suggesting an approach for enhancing screening accuracy.

    Tweet Tweets with this article
    • SCI members @johnwitte @Linda_Kachuri & others aim to make #PSAscreening more accurate by calibrating #PSAlevels to each man’s genetics. This could reduce overdiagnosis & better predict aggressive disease. https://t.co/XNFKOtjwX2 #CancerScreening #PersonalizedMedicine https://t.co/Ifxmj42NFY

  • Mashup Score: 0

    Artificial intelligence (AI) software developer Avenda Health said that its Unfold AI prostate cancer management platform has been used for the first time in a commercial setting.

    Tweet Tweets with this article
    • .@AvendaHealth reaches milestone with Unfold AI software for #prostatecancer management - Unfold AI combines patient-specific data from prostate imaging, biopsies, and #pathology to create a 3D cancer estimation map | #personalizedmedicine #Radiology https://t.co/b8OeSlt29N